RS2D
Desconocido
GAMMA-MRI: gamma MRI the future of molecular imaging
RS2D SAS
participó en un
H2020:
H2020-FETOPEN-2018-2020
Gamma-MRI will develop a clinical molecular imaging device based on the physical principle of anisotropic gamma emission from hyperpolarised...
2021-01-20 - 2024-09-30 | Financiado
2021-01-20 - 2024-09-30 | Financiado
AlternativesToGd: Hyperpolarised MR technologies and molecular probes as alternatives for conventional metal containin...
RS2D SAS
participó en un
H2020:
H2020-FETOPEN-2018-2020
Recently, the European Medicines Agency (EMA) and the U.S. Food & Drug Administration (FDA) recommended suspension and warning labels for Ga...
2019-09-24 - 2023-09-30 | Financiado
2019-09-24 - 2023-09-30 | Financiado
TRIMAGE: A dedicated trimodality PET MR EEG imaging tool for schizophrenia
RS2D SAS
participó en un
FP7:
"Schizophrenia is a severe mental disorder that manifests early in life and imposes a high social and economic burden on European societies....
Financiado
Financiado
* No se disponen de datos de la empresa actual.